Cleared Traditional

K842010 - THYROXINE-BINDING GLOBULIN RADIOUMMU

K842010 is the FDA 510(k) clearance for THYROXINE-BINDING GLOBULIN RADIOUMMU by Nichols Institute Diagnostics. It is a Class 2 Chemistry device (product code CEE) cleared through the Traditional 510(k) pathway after a 39-day FDA review.

K842010 · Nichols Institute Diagnostics · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1984
Decision
39d
Days
Class 2
Risk

K842010 is an FDA 510(k) clearance for the THYROXINE-BINDING GLOBULIN RADIOUMMU. Classified as Radioimmunoassay, Thyroxine-binding Globulin (product code CEE), Class II - Special Controls.

Submitted by Nichols Institute Diagnostics (Mchenry, US). The FDA issued a Cleared decision on June 25, 1984 after a review of 39 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1685 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Nichols Institute Diagnostics devices

Submission Details

510(k) Number K842010 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 17, 1984
Decision Date June 25, 1984
Days to Decision 39 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
49d faster than avg
Panel avg: 88d · This submission: 39d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CEE Radioimmunoassay, Thyroxine-binding Globulin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1685
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CEE Radioimmunoassay, Thyroxine-binding Globulin

All 15
Devices cleared under the same product code (CEE) and FDA review panel - the closest regulatory comparables to K842010.
T-UPTAKE MICROASSAY
K885034 · Diamedix Corp. · Feb 1989
TECHNICON RA(R) ANALYTE (TBG) (30 C AND 37 C)
K874658 · Technicon Instruments Corp. · Dec 1987
ENZYMUN TEST TBG
K862109 · Boehringer Mannheim Corp. · Jun 1986
VENTREZYME T4U IMMUNOASSAY T4U
K841024 · Ventrex Laboratories, Inc. · May 1984
ENDAB THYROID UPTAKE
K822684 · Immunotech Corp. · Oct 1982
TBG DIAGNOSTIC KIT
K820252 · Diagnostic Reagents, Inc. · May 1982